Innovations in clinical trial design like adaptive designs based on Bayesian statistics and master protocols have so far produced more enthusiasm than regulatory results, but the publication of data two cohorts from the adaptively randomized I-SPY 2 Phase II trial in the New England Journal of Medicine could go some way toward moving new designs from theory to more widespread practice.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?